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curs, such as in lymphatic malignancies or autoimmune
disorders. Therefore, B-cell depleting therapy with
Ritu ximab, an anti-CD20 chimeric monoclonal antibo -
dy, was first approved for non-Hodgkin lymphoma in
19972 and was later licensed for treatment of rheuma-
toid arthritis (RA) in patients with inadequate response
or intolerance to tumour necrosis factor (TNF) inhi -
bitors3. There is also growing evidence that Rituxi mab
may be effective and relatively safe in several other sys-
temic rheumatic diseases (SRD), especially in patients
refractory to first-line therapies.
We present a case series of eight patients with SRD
other than RA who were treated with Rituximab. 
clInIcAl cAses
Rituximab was introduced in our hospital for the treat-
ment of RA in 2007. Since then, there were eight pa-
tients with SRD treated off-label with this monoclonal
antibody in our rheumatology department, seven of
which were female patients. The mean age was 48,25
years (33 – 80) and they were all caucasian. Five of
those patients had an overlap syndrome consisting of
RA and Systemic Lupus Erythematosus (also known as
Rhupus), two had systemic lupus erythematosus (SLE)
and one had Wegener’s Granulomatosis (WG).
The five patients with Rhupus were all female and
had an mean age of 54,2 years (37 – 80). They had a
mean duration of disease of 14 years (9 – 30) and they
were treated with Rituximab after 11,6 years of disease
onset (5 – 28). One patient had a previous diagnosis of
SLE and presented with erosive polyarthritis; two pa-
tients had a previous diagnosis of RA and presented
with clinical features of SLE; the other two patients pre-
sented simultaneously with clinical features of SLE and
RA. By the time the diagnosis of Rhupus was made, two
patients had both positive rheumatoid factor (RF) and
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AbstrAct
B-cells play an important role not only in cellular but
also in humoral immunity through differentiation into
plasma cells and antibody production. B-cell depletion
may, theoretically, change the course of systemic
rheumatic diseases (SRD) in which self-reactive anti-
bodies are part of the pathogenic pathway. In Rheuma-
tology, anti-B-cell antibody Rituximab is currently li-
censed for the treatment of rheumatoid arthritis, how-
ever there is growing evidence of its potential use in
other SRD. The authors present a case series of eight pa-
tients in which Rituximab was used off-label including
overlap syndrome Rhupus, systemic lupus erythe-
matosus and Wegener’s granulomatosis. In the end, a
brief literature review about this subject is performed.
Keywords: Rhupus; Systemic Lupus Erythematosus;
Wegener’s granulomatosis; Rituximab; Off-label.
IntroductIon
In the past decades, advances in immunology and
molecular science have not only enriched the under-
standing of disease pathophysiology but also brought
new light on cutting edge therapies. The role of B-cells
in both innate an adaptive immunity as antigen-pre-
senting cells, producers of chemokines and cytokines
and as plasma cells precursors1 has made them capital
targets when abnormal immune system functioning oc-
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anti-citrullinated protein antibodies (ACPA); one pa-
tient had only positive RF; and the other had only posi -
tive ACPA (RF and ACPA were not available in one pa-
tient). All had an elevated titer of antinuclear antibody
(ANA) and positive anti-double stranded DNA antibo -
dy (anti-dsDNA). All patients had also been pre viously
treated with methotrexate (mean dosage of 21 mg/
/week), hydroxychloroquine (400 mg/day) and
predni sone (mean dosage of 8,5 mg/day). Four pa-
tients were treated with azathioprine (mean dosage of
125 mg/day). Only one patient received biologic thera -
py previous to Rituximab (Adalimumab, 40 mg every
other week for 3 years, suspended for secondary fai -
lure). The reason that led to treatment with Rituximab
was moderate (2 patients) and severe (3 patients) joint
disease activity as indicated by the Disease Activity
Score (DAS) 28, hence, the regimen used was two
1000 mg infusions two weeks apart in all 5 patients.
At week 24 after infusion there was a significant de-
cline in the mean 3-variable DAS 28 from 4,89 to 3,31
and in the mean 4-variable DAS 28 from 5,23 to 3,48.
At week 24 after infusion there was also a significant
reduction in mean standard treatment dosage, name-
ly in methotrexate (from 21 mg/week to 15 mg/week),
azathioprine (from 125 mg/day to 87,5 mg/day) and
prednisone (from 8,5 mg/day to 5 mg/day). Three of
the five Rhupus patients are currently in remission,
only one of them needing retreatment. The fourth pa-
tient, despite three retreatment courses, maintains se-
vere articular disease activity). The fifth patient didn’t
complete her first treatment because she had a severe
infusion-related reaction near the end of the treatment,
which led to drug discontinuation. There were no re-
ported infections in the follow-up period. 
We also had two SLE patients who were treated with
off-label Rituximab: a 33-year old female patient and
a 41-year old male patient with 5 and 12 years of disea -
se duration, respectively. The female patient was trea -
ted with Rituximab for a severe and refractory throm-
bocytopenia which was the presenting feature of her
disease along with malar rash, photosensitivity and ele -
vated ANA titer. Before the infusion, oral prednisone
1 mg/kg/day, intravenous methylprednisolone 1000
mg/day for three consecutive days and human im-
munoglobulin were used to try to reverse the severe
platelet depletion, with no success. She was treated
with weekly Rituximab 375 mg/m2 for four consecu-
tive weeks and a slight increase in platelet count was
obser ved, from 10,8x109/L to 36x109/L. Therefore,
posterior treatment with intravenous cyclophos-
phamide and mycophenolate mofetil was ensued and
the patient was discharged 3 months after admittance
with a platelet count of 158x109/L21. The male patient
was also trea ted with weekly Rituximab 375 mg/m2 for
four consecutive weeks for World Health Organization
(WHO) class IV + V lupus nephritis (LN) resistant to
intravenous cyclophosphamide, oral azathioprine and
oral mycophenolate mofetil. Previous to the infusion,
creatinine level was 1,02 mg/dL, 24 hour proteinuria
was 1,6 g, complement levels were low and dsDNA
antibody titer was high. At week 24 after treatment
creatinine was 0,99 mg/dL, 24 hour proteinuria was
370 mg and both complement and anti-dsDNA levels
were normal. Both female and male patient are cur-
rently in remission.
Our last case of off-label use of Rituximab refers to
a 41-year old female patient with glottic stenosis as a
complication of ANCA-negative WG. She had been
previously submitted to several bronchofibroscopies
as well as treatment with intravenous methylpredni -
solone, oral cyclophosphamide, azathioprine and
methotrexate. At week 24 after infusion of Rituximab
375 mg/m2 for four consecutive weeks there was still
need for bronchofibroscopic airway dilation proce-
dures, although an improvement in physical compo-
nents like asthenia and anorexia was referred. Table I
summarizes RTX off-label treatments.
dIscussIon
Self-reactive antibodies seem to play an important role
in several SRD, although their precise mechanism of
action is still subject of debate. For instance, in RA and
in SLE, RF and ANA, respectively, are thought to acti-
vate complement and trigger joint and systemic in-
flammation leading to tissue damage4,5. Consequently,
drugs that are used to deplete these antibodies may
have the potential to change SRD’s natural history.
Based in these premises, Rituximab has been used in
different clinical settings aside from those for which it
has been previously approved. The results have been
inconsistent.
In SLE, the two major randomized controlled trials
(RCT) of Rituximab in patients without renal involve-
ment (EXPLORER trial) and with renal involvement
(LUNAR trial) failed to meet their endpoints and thus
showed no benefit over standard of care therapy. Some
methodological issues such as concomitant therapies,
disease heterogeneity and limited follow-up might ex-
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plain this. Many open-label and retrospective studies,
as well as case series and case reports, have demons -
trated the clinical efficacy and safety of Rituximab in
SLE6. LN is a serious complication of SLE and influen -
ces morbidity and mortality. Ramos-Casals et al7 analy -
zed seven observational studies regarding the use of
Rituximab in LN, in a total of 106 patients. There was
a favorable response in 69% of them (half had a com-
plete response, the other half had a partial response)
with higher rates of response among patients with type
III LN and lower among patients with type V LN.  There
is also no consensus on the regimen that should be used
in SLE and LN. The majority of patients was treated
with two infusions of 1000 mg two weeks apart, but
375 mg/m2 weekly for four consecutive weeks was also
used. Aside from renal involvement, Rituximab may
have potential benefits in articular, cutaneous and
hematologic disease6,7. So far, the adverse events pro-
file has been acceptable (10% of serious infections)2,6,8. 
The overlap syndrome Rhupus was first described
by Schur in 19719 and it refers to a rare form of erosive
and deforming polyarthritis in patients with SLE, re-
sembling RA10. It affects only a minority of patients
(0,01-2%)11 and therefore there is scarce evidence on
the efficacy and safety of treatment using convention-
al and biologic drugs. Reports of small series of patients
show variable response to standard DMARD therapy12
including methotrexate, hydroxychloroquine and low-
-do se corticosteroids. Prabhakaran et al13 reported 3
ca s es of overlap syndrome Sjrupus (SLE, RA and Sjö-
gren’s syndrome) with significant clinical and labora-
torial response to Rituximab, although no dosing regi -
men is referred.  
There is also growing evidence on the role of Rituxi -
mab in ANCA associated vasculitis, namely WG. The
RAVE trial (Rituximab versus cyclophosphamide for
ANCA-associated vasculitis)14 and the RITUXVAS trial
(Rituximab versus cyclophosphamide in ANCA-asso-
ciated renal vasculitis)15 are two recent prospective RCT
that have shown that Rituximab is capable of inducing
remission with a favorable safety profile, presenting as
an alternative to cyclophosphamide and corticosteroid
regimens. The RAVE trial even showed superiority of
Rituximab in relapsing disease when compared to cy-
clophosphamide. Both trials used 375 mg/m2 per week
for four consecutive weeks. Several other retrospective
studies confirm these auspicious data. The Spanish
BIOGEAS Study Group demonstrated higher response
rates for renal (100%), neurological (80%) and pul-
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for ear, nose and throat (67%) and cutaneous (33%)
involvement16.
Promising results are also arriving from new trials
and also from case series and case reports on the use of
Rituximab in other refractory SRD such as inflamma-
tory myopathies17,18 and Sjögren’s syndrome19.  In sys-
temic sclerosis it may have a beneficial effect in lung
disease20. 
The authors decided to report these 8 clinical cases
to support bibliographic evidence that Rituximab may
be effective and safe in SRD other than RA. However,
this evidence comes mainly from uncontrolled trials
since SRD are rare and heterogeneous, which makes
trial design, outcome measurement and endpoint defi -
nition a difficult task. There is also no definition on
which dosing regimens should be used in the different
SRD settings. In most published studies, the most fre-
quent adverse events were infections. In our small se-
ries, no infection was reported in the follow-up period
although one serious infusion-related reaction oc-
curred. One of the main limitations of studies con-
cerning off-label use of Rituximab is the short follow-
-up period, which may underestimate the number of
adverse events as well as the frequency of relapses and
need for retreatment.
In conclusion, for the time being, off-label use of
Ritu ximab should be restricted to severe patients with
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